Thursday's Biggest Stock Stars
Yesterday's market is today's road map.
Kraft's Ever-Shifting Menu
Recent anemic results belie more promising future prospects.
Boeing's Continuing Climb
The company can consolidate its lead if it overcomes some challenges.
Merck's Special Interest
Merck is likely to succeed in getting states to mandate HPV vaccination.
Covance Stays Solid
Despite a run-up in the stock, Covance may be in for yet another solid year.
Southwest's Declining Edge?
Past advantages in fuel and labor expenses appear to be on the wane.
California Pizza Rising?
The company's EPS forecast is enticing, but is it enough to buy on?
Monsanto's Bigger Harvest?
High corn prices could allow Monsanto to raise seed prices and improve margins.
GM's Malibu Makeover
While it's no trailblazer, this new car model shows that the company is paying attention to the right things.
General Mills Rethinks Trix
The rise and fall of the company's low-sugar kids' cereals illustrates the pitfalls of responding hastily to media frenzies.
Novartis Cuts in Line at the Drugstore
Consolidation in pharmacy benefits management may leave Novartis most resistant to pricing pressure.
Defense Contractors Under Attack?
The stage could be set for budget shifts that will hurt some defense contractors and help others.
Monsanto Needs to Charm
The company has to confront concerns over genetically modified foods soon if it hopes to keep growing.
Yahoo!'s New Camera Crew
A new feature allows users the chance to make the news.
More Political Ire for Wal-Mart?
Christian conservatives could have had something to do with Wal-Mart's November weakness.
Hospira's Bold Move
The drug delivery outfit's stab at biosimilars is worth some attention, but investors shouldn't assume a major payoff.
Polo's Next Hurdle
The luxury goods purveyor looks poised to finish strong in fiscal 2007, but keeping up the pace will present a challenge.
Albany Molecular Plays the Odds
Will more investment in drug development hurt profitability?
Charles River Inches Forward
The company is not out of the woods yet, but some positive signs are emerging.
Novartis' China Gambit
Novartis probably won't get any near-term dividend from its China investment, but the nation is too big to ignore.